MapLight Therapeutics | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis	Alzheimer disease, Hallucinations, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, perceptual disorders, psychiatric disorder, tauopathy	Recruiting	Phase 2	2026-09-30		NCT06887192
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia	Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, brain disorder, central nervous system disorder, nervous system disorder, psychiatric disorder, schizophrenia	Recruiting	Phase 2	2026-09-01		NCT07459647
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis	Alzheimer disease, Hallucinations, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, perceptual disorders, psychiatric disorder, tauopathy	Enrolling by invitation	Phase 2	2026-08-07		NCT07459660
ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)	autism, autism spectrum disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder	Active, not recruiting	Phase 2	2026-07-20		NCT05889273